Premium
Anti‐diabetic efficacy of Fenfuroœ, a novel, patented Trigonella foenum‐graecum seed extract (1019.14)
Author(s) -
Bagchi Debasis,
Swaroop Anand,
Kumar Pawan,
Bagchi Manashi
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1019.14
Subject(s) - trigonella , metformin , glipizide , streptozotocin , diabetes mellitus , triglyceride , medicine , insulin , chemistry , zoology , endocrinology , traditional medicine , cholesterol , biology
Anti‐diabetic efficacy of a novel Trigonella foenum‐graecum seed extract (Fenfuro TM ) enriched in furostanolic saponins was investigated. Sprague‐Dawley rats were given high‐fat diet for 2 weeks followed by streptozotocin (STZ, 35 mg/kg ip). Animals were checked for plasma glucose level (PGL) 2 days post+STZ injection to confirm diabetes. Rats showed > 300 mg/dl of PGL were included. Fenfuro TM (150‐ and 450 mg/kg po) and glipizide (5 mg/kg po) were administered once daily for 20 days and then twice daily for 10 days over 30 days. Blood was collected on 0, 10, 20 and 30 days and estimated for fasting plasma triglyceride (PTG), TC and Insulin levels. On day 30, Fenfuro TM and glipizide‐treated diabetic animals were treated with/without metformin (100 mg/kg) twice daily for the next 10 days. Fenfuro TM didn’t affect the body weight, feed and water intake. Fenfuro TM (150 mg/kg po) reduced the PTG levels by 22%, 24.6% and 29% on 10‐, 20‐ and 30‐days of treatment, respectively, while glipizide (5 mg/kg po) reduced the PTG levels by 57.4%, 46.2% and 39.4%. Fenfuro TM (450 mg/kg) treatment exhibited significant hypoglycemic activity (31.5%) as compared to insulin (48.2% with 1 U/kg i.p.). Fenugreek (150 mg/kg po) and Metformin (100 mg/kg po) combination produced significant reduction in PGL (20.7%). These studies demonstrated the efficacy of this Fenfuro TM extract in type 2 diabetes. Grant Funding Source : Supported by Cepham Inc, NJ